Teva Pharmaceutical Industries (TEVA) Total Non-Current Liabilities (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Total Non-Current Liabilities for 18 consecutive years, with $18.3 billion the latest figure, recorded in Q1 2026.

• Quarterly Total Non-Current Liabilities fell 12.93% year-over-year to $18.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.3 billion (down 12.93% YoY) and the FY2025 annual result came in at $19.4 billion, down 6.87% from the prior year.
• Total Non-Current Liabilities retreated to $18.3 billion in Q1 2026 per TEVA's latest filing, from $19.4 billion in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for TEVA reached as high as $25.2 billion in Q1 2022 and fell as low as $18.3 billion in Q1 2026.
• A 5-year average of $22.3 billion and a median of $21.7 billion in 2024 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2023 — Total Non-Current Liabilities rose 0.44% — and 2026, when it declined 12.93%.
• Year by year, Total Non-Current Liabilities stood at $23.9 billion in 2022, then decreased by 3.5% to $23.1 billion in 2023, then fell by 9.94% to $20.8 billion in 2024, then retreated by 6.87% to $19.4 billion in 2025, then slipped by 5.69% to $18.3 billion in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $18.3 billion, $19.4 billion, and $21.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.